OmniAb Inc. (OABI), which licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics, has had a very strong start to the year and has raised its revenue guidance for 2026.
The company's technology platform is known as the OmniAb platform, and at its core is its proprietary Biological Intelligence, which harnesses the immune systems of transgenic animals to generate optimized antibody candidates for human therapeutics.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com